drugset / Trial / NCT00227461

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

NCT00227461

Phase 1 Unknown 50 enrolled Kessler Foundation UCB Pharma · collab
Non-randomizedCrossoverOpen-labelTreatment

Summary

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Timeline

Start
2005-09
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg Oral

Indications